Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
Webcasted presentation to take place at 1:10pm ET
網絡直播演講將於美國東部時間下午 1:10 舉行
DENVER, CO / ACCESSWIRE / November 30, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference on December 7, 2023.
科羅拉多州丹佛/ACCESSWIRE/2023年11月30日/專注於新型療法商業化的製藥公司Aytu BioPharma, Inc.（以下簡稱 “Aytu”）（納斯達克股票代碼：AYTU）今天宣佈，其首席執行官喬什·迪斯布魯將參加2023年12月7日的新興增長會議。
Mr. Disbrow will conduct a presentation and subsequently open the floor to questions. Please submit your questions in advance to Questions@EmergingGrowth.com.
迪斯布魯先生將主持演講，然後請大家提問。請提前將您的問題提交到 Questions@EmergingGrowth.com。
Management's presentation will be on Thursday, December 7th at 1:10pm ET. To register to stream the presentation live, visit this LINK or visit the Company's website.
管理層的演講將於美國東部時間12月7日星期四下午 1:10 舉行。要註冊直播演講，請訪問此鏈接或訪問公司的網站。
If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel,
如果與會者無法在會議當天現場參加活動，則還將在EmergingGrowth.com和新興增長YouTube頻道上提供存檔的網絡直播，
Management will also host one-on-one investor meetings after the conference. To request a virtual 1x1 meeting with the Aytu management team, please contact your respective Emerging Growth Conference representative or email the Company's investor relations team at AYTU@lythampartners.com.
會議結束後，管理層還將舉辦一對一的投資者會議。要申請與Aytu管理團隊進行虛擬的一對一會議，請聯繫您各自的新興增長會議代表或發送電子郵件至公司的投資者關係團隊，電子郵件地址爲 AYTU@lythampartners.com。
About Aytu BioPharma, Inc.
關於 Aytu BioPharma, Inc.
Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics. The Company's prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.
Aytu BioPharma是一家將商業處方療法產品組合商業化的製藥公司。該公司的處方產品包括用於治療注意力缺陷多動障礙 (ADHD) 的 Adzenys XR-ODT（苯丙胺）緩釋口解片（見完整處方信息，包括盒裝警告）和用於治療注意力缺陷多動障礙 (ADHD) 的 Cotempla XR-ODT（哌醋甲酯）緩釋口解片（參見完整處方信息，包括盒裝警告）、Karbinal ER（馬來酸卡比諾胺）釋放抗組胺懸浮液適用於治療多種過敏性疾病，還有 Poly-Vi-Flor 和 Tri-Vi-Flor，兩種基於氟化物的補充處方維生素產品線有多種配方可供缺氟嬰兒和兒童使用。要了解更多信息，請訪問 aytubio.com。
About the Emerging Growth Conference
關於新興增長會議
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
新興增長會議是上市公司在辦公室方便地以省時的方式向投資界展示和傳達其新產品、服務和其他重大公告的有效方式。
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
會議的重點和覆蓋範圍包括各個成長領域的公司，這些公司擁有強大的管理團隊、創新的產品和服務、有針對性的戰略、執行力以及長期增長的整體潛力。其受衆可能包括成千上萬的個人和機構投資者，以及投資顧問和分析師。
All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
所有會議將通過視頻網絡直播進行，將在東部時區舉行。
Contacts for Investors:
投資者聯繫方式：
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com
馬克·奧基，首席財務官
Aytu BioPharma, Inc.
moki@aytubio.com
Robert Blum or Roger Weiss
Lytham Partners
AYTU@lythampartners.com
羅伯特·布魯姆或羅傑·魏斯
萊瑟姆合作伙伴
AYTU@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
來源：Aytu BioPharma, Inc.
譯文內容由第三人軟體翻譯。